Published on in CHOP News
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
Published on in CHOP News
Four CHOP researchers are part of a world-class research team that will receive $25 million to study solid tumors in children, funded by Cancer Grand Challenges.
Published on in CHOP News
A group of researchers that includes CHOP presented new data on CRISPR-edited gene therapy for blood disorders at an international meeting.
Published on in CHOP News
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
Published on in CHOP News
Prestigious award recognizes Dr. High’s contribution to improving children’s health through her gene therapy research, which began during her time at CHOP.
Whitehead received life-saving treatment at CHOP, under the care of Dr. Stephan Grupp, transforming the field of cancer immunotherapy.
Read morePublished on in CHOP News
Emily Whitehead, now 17, received life-saving treatment at CHOP, transforming the field of cancer immunotherapy.
Published on in CHOP News
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
Published on in CHOP News
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Published on in CHOP News
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.